NAT-105 : A Feasibility Study of the Nativis Voyagerâ„¢ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

UnknownPhase Unknown

18+Age Over 18

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

| Brain and spinal cordGlioblastoma (GBM), Glioma

Trial Overview Read MoreRead more

This study will assess the effects of Nativis Voyager therapy in patients with recurrent Glioblastoma (GBM)..
 

This trial is treating patients with Glioblastoma.

You may be able to join this trial if:

  • You have had treatment, but your cancer has come back.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have had certain treatments, surgical procedures or drugs.
  • You have a certain disease or psychological condition.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Feasibility Study of the Nativis Voyagerâ„¢ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia

Commercial Sponsor

Nativis, Inc.

Summary

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to eleven subjects over six months. Safety and clinical utility will be evaluated.

Recruiting Hospitals Read MoreRead more

St Vincent's Hospital, Medical and Radiation Oncology
Fitzroy
Ms Nadia Ranieri
oncology.research@svha.org.au
03 9288 3167

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next